Score Overview
Explore the 2021 public Archive ranking →
Where Seres Therapeutics Inc has ranked, year by year
Showing 1 year ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- MCRB
2020: 35.7% · 2021: 76.2% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-30 | $ 3.35 | — |
1 Year2025-09-30 | $ 19.24 | -82.59% |
5 Years2021-09-30 | $ 139.20 | -97.59% |
10 Years2016-09-30 | $ 245.80 | -98.64% |
All Time2015-06-26 | $ 1.03K | -99.67% |
| Period | Last Price2026-09-30 | 1 Year2025-09-30 | 5 Years2021-09-30 | 10 Years2016-09-30 | All Time2015-06-26 |
|---|---|---|---|---|---|
| Price | $ 3.35 | $ 19.24 | $ 139.20 | $ 245.80 | $ 1.03K |
| Return | — | -82.59% | -97.59% | -98.64% | -99.67% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in USD
| Year | |||
|---|---|---|---|
| TTM | $ 1M | -$ 22M | $ 15M |
| 2025 | $ 789K | $ 5M | $ 45M |
| 2024 | $ 0.00 | -$ 146M | $ 30M |
| 2023 | $ 126M | -$ 113M | $ 127M |
| 2022 | $ 7M | -$ 250M | $ 181M |
| 2021 | $ 144M | -$ 65M | $ 290M |
| 2020 | $ 33M | -$ 89M | $ 253M |
| 2019 | $ 34M | -$ 70M | $ 94M |
| 2018 | $ 28M | -$ 98M | $ 85M |
| 2017 | $ 32M | -$ 89M | $ 149M |
| 2016 | $ 21M | -$ 91M | $ 193M |
| IPO2015 | $ 0.00 | -$ 54M | $ 205M |
Seres Therapeutics Inc fundamental performance
Between 2020 and 2025, revenue declined from $ 33M to $ 789K and net income went from -$ 89M to $ 5M. Revenue increased in 3 of those 5 years; net income in 2.
Between 2015 and 2025, revenue grew from $ 0.00 to $ 789K and net income went from -$ 54M to $ 5M. Revenue increased in 6 of those 10 years; net income in 5.
Seres Therapeutics Inc currently holds a 5-year HDB Score of 4.3 out of 10. How the HDB Score is calculated.
Membership
Continue MCRB’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
